LXRX News and Press, Lexicon Pharmaceuticals Inc. From 05/05/22

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2022 Results Conference Call May 05, 2022 08:00 AM ET Company Participants Charles Schultz - Investor Relations Lonnel Coats - President and Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice Presi...

Lexicon Pharmaceuticals press release (NASDAQ:LXRX): Q1 GAAP EPS of -$0.16 beats by $0.01. Revenue of $0.04M (+33.3% Y/Y) misses by $0.01M. As of March 31, 2022, Lexicon had $86.5 million in cash and investments, as compared to $86.7 million as of December 31, 2021. For further details see:...

THE WOODLANDS, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones. “We plan to resubmit our New Drug Application (NDA) fo...

Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $0.05M For further details see: Lexicon Pharmaceuticals Q1 Earnings Preview

THE WOODLANDS, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET /...

THE WOODLANDS, Texas, April 07, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will present at the 21 st Annual Needham Virtual Healthcare Conference on Tuesday, Apri...

Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society of America New guidelines recommend the use of SGLT inhibitors for the prevention and treatment of heart failure and highlight the need to improve optimization...

THE WOODLANDS, Texas, April 02, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results of a new analysis of data from the SCORED Phase 3 clinical trial of sotagliflozin that was presented at the American College of Cardiology’s 71st Annu...

THE WOODLANDS, Texas, March 21, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that an analysis of sotagliflozin data from the SCORED Phase 3 clinical trial will be presented as a late-breaker at the American College of Cardiology’s 71st...

Lexicon Pharmaceuticals (NASDAQ:LXRX) has entered into a $150M loan facility with Oxford Finance to provide commercial preparations and support the potential launch of sotagliflozin in heart failure. The loan facility consists of four tranches. The first three are for $25M each, while the fou...